|
What can you do to avoid catching a cold?
Thursday, January 01, 2009 10:46 AM
|
•If possible, stay away from people with colds.
•Avoid crowded places where the risk of infection is greater.
•Do not touch your nose or eyes after being in physical contact with
somebody that has a cold.
•Wash your hands thoroughly, especially after blowing your nose.
•Keep rooms well aired.
OUT LOOK
Usually a common cold causes no serious trouble and symptoms will clear
up in one to two weeks. Possible complications include inflammation of
the eyes, sinusitis, inflammation of the middle ear, tonsillitis, and
pneumonia.
if you have any further queries please feel free to contact us.
|
|
|
|
|
|
|
|
Punjab to be liberated of fake medicines
Tuesday, December 23, 2008 12:52 PM
|
Punjab Chief Minister Mian Muhammad Shahbaz Sharif has said that resources are being utilized all out for providing better healthcare and treatment facilities to the masses and Mayo hospital would be made a model hospital according to its past traditions.
He said that three taskforces had been constituted for the provision of quality medicines to the people and eradication of spurious medicines. The taskforces were taking action against the persons involved in the heinous business of spurious medicines, which will purge Punjab of spurious medicines within few days, he added.
He said this during a presentation given by Dr Amir Afzal and Moazzam Ameer Ali on ‘Healthcare Management System’ here on Saturday.
Members Provincial Assembly Dr Saeed Elahi, Dr Ashraf Chohan, Karamdad Wahla, Dr Amir Aziz, Dr Majeed Ch, Dr Zahid Pervaiz, Dr Faisal and Special Secretary Health were also present on the occasion.
|
|
|
|
|
|
|
|
GlaxoSmithKline to buy Bristol-Myers Squibb's Pakistani
Tuesday, December 23, 2008 12:50 PM
|
GlaxoSmithKline, continuing a small buying spree in emerging markets, has agreed to pick up Bristol-Myers Squibb's Pakistani business for about $36.5 million.
Glaxo says it will acquire a portfolio of more than 30 pharmaceutical brands, including antibiotics, vitamins and dermatology products. Total sales of the portfolio in 2007 were about $19 million.
“We are continuing to make investments in emerging markets to grow and diversify GSK’s business," Abbas Hussein, GSK's president of emerging markets, said in a written release. "This acquisition reinforces our commitment to Pakistan, broadening our product portfolio and helping us to meet the needs of patients."
Glaxo, like many big pharmaceutical companies, faces a slowing pipeline of drugs from its R&D efforts as well as increased competition from generic drugmakers. In response, CEO Andrew Witty, who took the helm earlier this year, has said that GSK will increasingly look outside its own walls for growth.
That includes an emphasis on emerging markets. The relatively small deals GSK is making in the space won't have too much of an immediate impact, but the company says emerging markets will account for 40 percent of growth in the worldwide pharmaceutical industry by 2020.
Already this year, GSK has purchased a portfolio of drugs from Bristol-Myers Squibb in Egypt. The company also announced a drug commercialization deal with the South African pharmaceutical company Aspen.
GlaxoSmithKline, which has headquarters in London, employs more than 5,000 people in the Triangle.
|
|
|
|
|
|
|
|
Pak Govt blocks import of Indian drugs
Tuesday, December 23, 2008 12:49 PM
|
Pakistan government has blocked a proposal for importing 400 medicines from India following intense lobbying against the move by the local pharmaceutical industry.
The proposal forwarded by Pakistan's commerce ministry was stalled ahead of an expected hike of upto 40 per cent in the prices of life-saving drugs in the country.
Prime Minister Yousuf Raza Gilani has reportedly issued a direction that no drug produced in Pakistan should be imported. Gilani also sought justification for importing from India 13 vaccines and some oncology drugs that are currently not produced in Pakistan, sources told The Dawn newspaper.
However, the import of these vaccines and oncology products will continue.
Health Secretary Khushnood Lashari will meet Commerce Secretary Asif Shah to ensure that the proposal for importing Indian drugs is closed.
|
|
|
|
|
|
|
|
Abbott to buy Isis unit for $215 million
Thursday, December 18, 2008 3:30 PM
|
|
Abbott has exercised its option to purchase the remaining equity ownership in Ibis Biosciences Inc. from parent company Isis Pharmaceuticals Inc. (ISIS:Isis Pharmaceuticals Inc
Abbott also invested $40 million earlier this year, the pharmaceutical company said the total cost for the Ibis acquisition is $215 million. In addition, Isis will receive earn-out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits, Abbott said. Ibis is the developer of the Ibis T5000 Biosensor System for rapid identification and characterization of infectious agents
|
|
|
|
|
|
|
|
|